Stockreport

Arcutis Biotherapeutics: Behind The Big Rally [Seeking Alpha]

Arcutis Biotherapeutics, Inc. - Common stock  (ARQT) 
PDF Zoryve, now approved for numerous indications, is gaining traction as physicians shift away from steroids, supporting management's $2.6–$3.5B peak net revenue forecast. [Read more]